发明授权
EP0956034B1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION, AUTOIMMUNE OR INFLAMMATORY CONDITIONS COMPRISING CYCLOSPORIN A AND 40-0-(2-HYDROXYETHYL)-RAPAMYCIN
失效
带有锁定对移植物排斥，自身免疫性疾病和炎症WHAT环孢菌素A和40-O-（2-羟基乙基）组合制剂 - 雷帕霉素CONTAINS
- 专利标题： PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION, AUTOIMMUNE OR INFLAMMATORY CONDITIONS COMPRISING CYCLOSPORIN A AND 40-0-(2-HYDROXYETHYL)-RAPAMYCIN
- 专利标题（中）： 带有锁定对移植物排斥，自身免疫性疾病和炎症WHAT环孢菌素A和40-O-（2-羟基乙基）组合制剂 - 雷帕霉素CONTAINS
-
申请号： EP97937526.8申请日： 1997-07-29
-
公开(公告)号： EP0956034B1公开(公告)日： 2002-08-21
- 发明人: ZENKE, Gerhard , SCHUURMAN, Hendrik, J. , HAEBERLIN, Barbara , MEINZER, Armin
- 申请人： Novartis AG
- 申请人地址： Lichtstrasse 35 4056 Basel CH
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： Lichtstrasse 35 4056 Basel CH
- 代理机构： Becker, Konrad
- 优先权： GB9615942 19960730; GB9705684 19970318
- 国际公布： WO98004279 19980205
- 主分类号： A61K38/13
- IPC分类号： A61K38/13 ; A61K31/445 ; A61P37/00 ; A61P29/00
摘要：
A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
信息查询
IPC分类:
